NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $165K rose 16400.0% year over year, ahead of the +6020.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 65.0% from the prior quarter. Over 3 fiscal years it compounded at +229.4% a year.
Context
- Depreciation & amortization amounted to 11.7% of revenue in FY2025.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +16400.0% holds above the trailing-twelve-month pace of +6020.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 143K USD
- Year-over-year change
- +2760.0%
- 4-year CAGR
- +190.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 143K | +2760.0% |
| FY2024 | 2024-12-31 | 5K | +0.0% |
| FY2023 | 2023-12-31 | 5K | +25.0% |
| FY2022 | 2022-12-31 | 4K | +100.0% |
| FY2021 | 2021-12-31 | 2K | — |
Depreciation & Amortization vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's LTM Mar 2026 depreciation & amortization of $306K is the 5th highest of the 9 companies compared; the peer median is $717.15K.
- Its year-over-year change of +6020.0% is the highest of 9, against a peer median of +5.2%.
- Depreciation & amortization amounts to 13.3% of revenue for NRXP, versus a peer median of 17.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.88M | -3.1% | +15.8% | — | |
| LTM Jun 2026 | $3.65M | +111.3% | +14.0% | 17.4% | |
| LTM Mar 2026 | $3.01M | +10.5% | +24.4% | 9.2% | |
| LTM Mar 2026 | $1.17M | +6.7% | +6.9% | 82.6% | |
| LTM Mar 2026 | $306K | +6020.0% | +229.4% | 13.3% | |
| LTM Mar 2026 | $267K | +621.6% | -34.3% | — | |
| LTM Mar 2026 | $187K | -43.8% | -21.9% | 0.1% | |
| LTM Mar 2026 | $119.64K | +3.7% | -17.0% | 35.9% | |
| LTM Mar 2026 | $107K | -22.5% | -0.6% | — | |
| Peer median (excluding NRXP) | $717.15K | +5.2% | +3.2% | 17.4% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 1.23M |
| Cost of Revenue | 2K | 4K | 5K | 5K | 505K |
| Gross Profit | (2K) | (4K) | (5K) | (5K) | 720K |
| Gross Margin | — | — | — | — | 58.8% |
| Research & Development | 20.26M | 17.03M | 13.37M | 6.2M | 3.78M |
| Selling, General & Admin | 74.94M | 27.3M | 14.21M | 13.5M | 13.06M |
| Operating Expenses | 95.2M | 44.33M | 27.58M | 19.7M | 16.94M |
| Depreciation & Amortization | 2K | 4K | 5K | 5K | 143K |
| EBITDA | (93.04M) | (39.75M) | (30.03M) | (24.04M) | (27.81M) |
| EBITDA Margin | — | — | — | — | -2270.0% |
| Operating Income | (95.2M) | (44.34M) | (27.59M) | (19.7M) | (16.22M) |
| Operating Margin | — | — | — | — | -1324.4% |
| Interest Income | 18 | 249K | 494K | 44K | 12K |
| Interest Expense | 18K | 0 | 120K | 1.08M | 671K |
| Other Income / Expenses | 2.14M | 4.58M | (2.56M) | (5.42M) | (12.4M) |
| Income Before Tax | (93.06M) | (39.75M) | (30.15M) | (25.13M) | (28.62M) |
| Pre-Tax Margin | — | — | — | — | -2336.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (93.06M) | (39.75M) | (30.15M) | (25.13M) | (28.62M) |
| Net Margin | — | — | — | — | -2336.5% |
| EPS (Basic) | (7.44) | (0.60) | (3.98) | (2.39) | (1.34) |
| EPS (Diluted) | (7.44) | (0.60) | (3.98) | (2.39) | (1.34) |
| Weighted Avg Shares | 46.92M | 65.77M | 7.58M | 10.52M | 21.4M |
| Weighted Avg Shares (Diluted) | 46.92M | 65.77M | 7.58M | 10.52M | 21.4M |
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.